{'fraction_non_alphanumeric': 0.05185758513931889, 'fraction_numerical': 0.005417956656346749, 'mean_word_length': 5.369458128078818, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The COMET trial.

A roundtable discussion by cardiac specialists and pharmacologists was convened on August 18, 2003, to discuss and critique the results of the Carvedilol or Metoprolol European Trial (COMET), which were recently published in The Lancet.1 Michael R. Bristow, MD, PhD, Head of the Division of Cardiology at the University of Colorado Health Sciences Center in Denver, CO, moderated the discussion. Panelists included Kirkwood F. Adams, Jr., MD, Associate Professor of Medicine and Radiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Jerry L. Bauman, PharmD, Professor of Pharmacy Practice and Medicine, University of Illinois at Chicago, Chicago, IL; Arthur M. Feldman, MD, PhD, Magee Professor of Medicine, Jefferson Medical College, Philadelphia, PA; Thomas D. Giles, MD, Professor of Medicine, Louisiana State University School of Medicine, New Orleans, LA; Sidney Goldstein, MD, Professor of Medicine, Case Western Reserve University, Detroit, MI; Douglas L. Mann, MD, Professor of Medicine, Winters Center for Heart Failure Research, Houston, TX; and Robert L. Talbert, PharmD, Professor of Pharmacy, University of Texas at Austin, Professor of Pharmacology and Medicine, University of Texas Health Science Center, San Antonio, TX.